Comparison of Different Types and Regimens of Intravenous Immune Globulin (IVIG) in Patients with Kawasaki Disease
|
|
- Domenic Sutton
- 6 years ago
- Views:
Transcription
1 Original Article Acta Cardiol Sin 2004;20:15 20 Pediatric Cardiology Comparison of Different Types and Regimens of Intravenous Immune Globulin (IVIG) in Patients with Kawasaki Disease Chi-Ming Liang, 1 Pi-Chang Lee, 1 Betau Hwang, 1,2 Jen-Her Lu, 1 Ping-Yao Wang, 1 Chen-Hsiang Lien 1 and C.C. Laura Meng 1 Object: To evaluate the effect of different types and regimens of high-dose intravenous immune globulin (IVIG) on patients with Kawasaki Disease. Patients: From June 1994 to May 2002, 120 patients who met the diagnostic criteria of Kawasaki Disease (KD) at our institution were reviewed. Of them, 99 who had complete data were enrolled in this study. Before IVIG therapy, 25 (25.3%) of 99 patients had coronary artery involvement. Methods: Patients with KD were given a different brand and dosage of IVIG when available in the hospital in random order. They were divided randomly into 4 groups with different types and regimens of high-dose IVIG. Group I (33 cases)- G regimen, 400 mg/kg/day 5 days; Group II (47 cases)- G regimen, 2 gm/kg 1 dose; Group III (10 cases)- I regimen, 400 mg/kg/day 5 days; Group IV (9 cases)- I regimen, 2 gm/kg 1 dose. Patients data were collected including: 1. age and sex; 2. symptoms and signs; 3. fever lasting days after IVIG; 4. echocardiographic findings (before IVIG, at acute stage, at convalescent stage, and long term follow-up); 5. retreatment with IVIG. Results: 1. There were some differences in the clinical features, including sex, age, duration of fever before administration of IVIG, and diagnostic criteria of Kawasaki Disease among the 4 groups; 2. The durations of fever lasting after administration of IVIG were , , , and days in Groups I, II, III and IV, respectively; 3. Two-dimensional echocardiographic evidence of coronary arterial dilatation/aneurysm detected before IVIG in Groups I, II, III and IV were, respectively, 36.4%, 40.4%, 30.0%, and 11.1%, at acute stage were 60.6%, 44.7%, 20%, and 22.2%, at convalescent stage were 12.1%, 17.0%, 0%, and 0%, and at long-term follow-up were 12.1%, 12.8%, 0%, and 0%. 4. The rates of retreatment with IVIG were 9.1%, 8.5%, 10%, 11.1% in Group I, II, III and IV, respectively. Conclusions: 1. Treatment of Kawasaki Disease with the regimen of 2 gm/kg one dose of IVIG had a better effect to shorten the duration of fever than that with 400 mg/kg/day 5 days. 2. G and I regimens seemed to make a difference in prevention of coronary dilation/aneurysm at acute stage, although the difference was without statistical significance; and there were no statistical differences in convalescent stage, long-term follow-up and retreatment, even for different dosages and brands. 3. If the patients with coronary abnormalities before IVIG were excluded, coronary abnormality prevention rates were 50.0%, 49.2%, 100%, and 100%, respectively, by the four different regimens of IVIG. Key Words: Intravenous immune globulin (IVIG) Kawasaki Disease Coronary artery Received: April 29, 2003 Accepted: June 16, Division of Pediatric Cardiology, Taipei Veterans General Hospital; 2 National Yang-Ming University, Taipei, Taiwan. Address correspondence and reprint requests to: Dr. Pi-Chang Lee, Department of Pediatrics, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan. Tel: ext. 102; Fax: ; liangcm5953@yahoo.com.tw INTRODUCTION Kawasaki Disease, or mucocutaneous lymph node syndrome, is an acute pediatric disorder characterized by fever, truncal rash, conjunctival injection, inflammation 15 Acta Cardiol Sin 2004;20:15 20
2 Chi-Ming Liang et al. of the oral mucosa, cervical adenopathy, edema, erythema and desquamation of hands and feet. 1 Originally recognized in Japan, cases of Kawasaki Disease have now been reported throughout the world. Taubert et al. 2 estimated the minimal incidence of Kawasaki Disease in the United States to be 2000 cases per year. Kawasaki Disease is self-limited in the majority of afflicted patients and cause unknown. 3 Between 20% and 25% of patients, however, develop coronary abnormalities, including ectasia, aneurysm, stenosis and thrombosis, that may lead to myocardial ischemia, infarction and sudden death. 4 Because of its anti-inflammatory and antithrombotic action, aspirin has generally been used in the treatment of Kawasaki Disease. 5,6 The data presented indicate that intravenous administration of immune globulin (IVIG) also has an important role in the management of this disorder. 7 Intravenous administration of high-dose immune globulin (IVIG) early in the course of Kawasaki Disease (KD) is well-known to reduce the incidence of coronary arterial lesion from 40% to 20% at acute stage and from 20% to less than 10% at convalescent dosage The Japanese Ministry of Health suggested that current treatment is more than 95% effective in preventing coronary artery changes. Echocardiographic measurements adjusted for body size imply a far higher incidence of coronary artery dilation despite prompt therapy. 11 Considering chronic alterations in endothelial function after KD, more effective management of acute and recurrent KD are needed. But the effects of different compositions and dosage of immune globulin to prevent the occurrence of coronary arterial lesion in patients with Kawasaki Disease need to be studied; such study was the purpose of this investigation. METHODS Patients The study participants were 120 patients who met the diagnostic criteria of Kawasaki Disease (KD), reviewed at our institution from June 1994 to May Ninety-nine of them who had complete data were enrolled for study. Twenty-five (25.3%) cases with coronary artery involvement were noted before IVIG therapy. Patients with KD were given a different brand and dosage of IVIG available in the hospital in random order. They were divided randomly into 4 groups with different types and regimen, which included: Group I (33 cases)- G regimen, 400 mg/kg/day 5 days; Group II (47 cases)- G regimen, 2 gm/kg 1 dose; Group III (10 cases)- I regimen, 400 mg/kg/day 5 days; and Group IV (9 cases)- I regimen, 2 gm/kg 1 dose. G regimen (Gamimune N, Cutter Biological, Berkeley, CA, USA, a division of Miles Laboratories, Inc.): The G regimen is a kind of human immunoglobulin containing a broad spectrum of opsonic and neutralizing IgG antibodies. It is produced by using cold ethanol fractionation of large pools of human plasma, isolated by diafiltration and ultrafiltration, and manufactured from pools of at least 1000 donors. Each milliliter (ml) contains 50 mg of protein, of which at least 98% is gamma globulin. Not less than 90% of which gamma gobulin is monomer, present trace of IgA and IgM. The distribution of subclasses is similar to that found in normal plasma (Table 3). Mean half-life was found to be days and range 19 days to 52 days. I regimen (Intraglobin F, Biotest Pharma, GmbH, Dreieich, Germany): The I regimen works through its neutralizing effect that increases the opsonisation of toxins and microorganisms. It is manufactured by pooling of plasma from more than 1000 healthy donors. 1 ml solution contains human plasma protein 50 mg, of which immunoglobulin is at least 95%. The patients data included: age and sex; symptoms and signs; fever lasting days after IVIG; echocardiographic abnormalities before IVIG, at acute stage, convalescent stage, and long-term follow-up; and retreatment with IVIG. The coronary abnormalities criteria were 1) internal diameter greater than 3 mm in children younger than 5 years of age, 2) internal diameter greater than 4 mm in children older than 5 years of age, 3) internal diameter of a segment 1.5 times greater than that of an adjacent segment, and 4) irregular coronary artery lumen. 10 Two-dimensional echocardiography (2DE) was performed periodically before and after the administration of IVIG. Cardiac catheterization and coronary angiography was performed in patients with abnormal 2DE following or with symptoms and signs of myocardial ischemia. Statistical analysis The descriptions of basic data, such as age and sex, were presented as mean value ( SD) and percentage. Acta Cardiol Sin 2004;20:
3 Intravenous Immune Globulin in Kawasaki Disease Analysis of variance (ANOVA) test (2-sided test) was used to compare the basic data with continuous clinical features as independent variables. Additionally, the categorical clinical feature variables were compared using Chi-Square test (2-sided test). To investigate the difference for the incidence of coronary arterial lesion in the 4 groups, Chi-Square test (2-sided test) and Fisher s exact test (2-sided test) were undertaken with the five categorical variables, Before IVIG, Acute stage, Convalescent stage, Long-term follow-up and Re-treatment rate. The advantage of Fisher s exact test (2-sided test) was applicable to the rare data set. Finally, to understand the varieties of IVIG effect in each group, the three categorical variables, acute stage, convalescent stage and long-term follow-up, were analyzed by McNemar s test (2-sided test). It was suitable to analyze matched-pair data structures by utilizing McNemar s test (2-sided test). We set the significance level in all tests as > RESULTS The clinical features including sex, age, duration of fever before administration of IVIG, and diagnostic criteria of Kawasaki disease were somewhat different among these 4 groups (Table 1). The durations of fever lasting after administration of IVIG were , , , and days in Group I, II, III, and IV, respectively (Table 1). We compared these 4 groups; for shorter lasting fever days, IVIG with 2 gm/kg/day 1 dose was better than 400 mg/kg/day 5daysinbothG and I regimen (I vs. II, p < 0.05, III vs. IV, p < 0.05) and there were no statistical differences among G and I regimens (I vs. III, p > 0.05, II vs. IV, p > 0.05) (Table 1). Two-dimensional echocardiographic evidence of coronary arterial dilatation/aneurysm was detected in 36.4%, 40.4%, 30.0%, and 11.1% before IVIG, 60.6%, 44.7%, 20.0%, and 22.2% at acute stage, and 12.1%, 17.0%, 0%, and 0% at convalescent stage in Groups I, II, III and IV, respectively (Table 2). And the rates of retreatment with IVIG were 9.1%, 8.5%, 10%, 11.1% in Groups I, II, III and IV, respectively (Table 2). We also compared at acute stage: I vs. II, II vs. III, II vs. IV, III vs. IV were all p > 0.05, but I vs. III and I vs. IV were both p < 0.05; this means I regimen was better than G regimen in 400 mg/kg/day 5daysor2gm/kg 1 doses (Table 2). Then we compared at convalescent, long-term follow-up, retreatment with IVIG rate: I vs. II, I vs. III, I vs. IV, II vs. IV, II vs. IV, and III vs. IV all were p > Table 2. Echocardiographic coronary abnormalities in different groups and comparisons Groups I (n = 33) II (n = 47) III (n = 10) IV (n = 9) Before IVIG 12 (36.4) 19 (40.4) 3 (30.3) 1 (11.1) Acute stage 20 (60.6)* 21 (44.7) 3(20)* 2(22.2) Convalescent stage 4 (12.1) 8(17) 0(0)** 0(0)** Long term follow up 4 (12.1) 6(12.8) 0(0)** 0(0)** Re-treatment 3 (9.1) 4 (8.5) 1 (10) 0 (0) Data are presented as the mean SD or number (%); *I vs. III, Fisher s exact test: p = 0.034;** unable to estimate the statistics; group I and II: acute stage vs. convalescent stage, acute stage vs. long-term follow-up, all p < 0.05 (by McNemar s test); group I and II: convalescent stage vs. long-term follow-up, p > 0.05 (by McNemar s test); unable to estimate the statistics. Table 1. General data of different groups, duration of fever after IVIG Group I (n = 33) II (n = 47) III (n = 10) IV (n = 9) Male/Female 13/20 19/28 8/2 8/1 Mean age SD (year old) Clinical manifestations Fever 5 days 32 (97) 43 (91.5) 8 (80) 9 (100) Limbs indurations 22 (66.7) 26 (55.3) 7 (70) 2 (22.2) Tips desquamation 15 (44.5) 19 (40.4) 5 (50) 3 (33.3) Rashes 28 (84.9) 41 (87.2) 8 (80) 9 (100) Conjunctival congestion 29 (87.9) 41 (87.2) 9 (90) 9 (100) Oral redness 32 (97) 46 (97.9) 10 (100) 9 (100) Cervical lymphoadenopathy 21 (63.6) 22 (46.8) 8 (80) 4 (44.4) Duration of fever after IVIG (Mean SD) days * * ** ** *I vs. II, p < 0.05; ** III vs. IV, p < 0.05; Data are presented as the mean SD or number (%). 17 Acta Cardiol Sin 2004;20:15 20
4 Chi-Ming Liang et al. Figure 1. Echocardiographic evaluations of coronary abnormalities in different groups of patients. 0.05; which means there were no statistical differences among G regimen and I regimens even in 400 mg/kg/day 5daysorin2gm/kg 1 dose (Table 2). We also compared at acute stage, at convalescent, and long-term follow-up s coronary abnormality rates by McNemar s test in different groups, which showed that IVIG use could improve coronary abnormality in subsequent echocardiographic studies (Table 2, Figure 1). DISCUSSION The coronary abnormality rates before the IVIG therapy were higher than in previous reports, possibly because our hospital is a tertiary medical center which usually accepts referral patients in more serious condition. 12 To shorten the fever days, 2 gm/kg 1 dose had better effect than 400 mg/kg/day 5 days, a finding similar to Barron et al. s report in 1990 in which 1 gm/kg single dose was more effective than 400 mg/kg/day 4 days to shorten the duration of fever after IVIG. 13 Hwang et al. have reported no difference in the prevalence of coronary aneurysm between the groups of a single high dose and multiple doses, although the single high dose of IVIG could improve the clinical symptoms more quickly and shorten the duration of hospitalization. 14 Sato N, et al. reported that the incidence of coronary artery complications in the 2 g group was significantly lower than in the 400 mg group. 15 The duration of high fever, positive duration of C-reactive protein and the hospital days in the 2 g group were all significantly shorter than in the 400 mg group. 15 Tsai et Table 3. IgG subclass in plasma and IVIG analysis IgG subclass G regimen I regimen Plasma IgG % 62% 60% IgG % 34% 29.4% IgG 3 6.3% 0.5% 6.5% IgG 4 5.1% 3.5% 4.1% al. reported that G regimen was better than the other brands in preventing coronary dilation and lowering retreatment rate. 16 In our data, G regimen appeared to make lower retreatment rate than I regimen, but the difference was not significant (because numbers of I regimen were too small). According to the instructions of product, preparation, methods and compositions of G and I regimens were nearly alike, except that IgG 3 and IgG 4 in G regimen were slightly higher than in I regimen (Table 3). The number of patients in Group III and Group IV was small, and the coronary artery abnormality rate in Group I was higher in our study than other groups; all the above may lead to some bias appearance, especially the coronary artery abnormality rates in convalescent and long-term follow-up of Group III and Group VI being zero, which made our comparison doubtful. So, in the future, we should collect more cases of Group III and Group IV, in order to reduce bias in different groups. Results in Table 2 and Figure 1 confirm that IVIG used can improve coronary abnormality rate over time. The 4 groups compositions, including sex and age, were different, which may produce some bias in later comparison between groups; but for before IVIG echocardiographic coronary abnormalities, we compared Acta Cardiol Sin 2004;20:
5 Intravenous Immune Globulin in Kawasaki Disease all groups; all p values were greater than 0.05, so there were no echocardiographic coronary abnormality rate differences before IVIG, and then later comparisons were meaningful. In the future, we will design for different sexes and ages for IVIG therapy study, in order to rule out the influence of age and sex. CONCLUSIONS Treatment of Kawasaki disease with a regimen of 2 gm/kg one dose of IVIG has a better effect to shorten the duration of fever than that of 400 mg/kg/day 5 days. G and I regimens seemed to make a difference in the prevention of coronary dilation/aneurysm at acute stage; I regimen was better than G regimen, but there was no statistically significant difference in convalescent stage, long-term follow-up and retreatment with IVIG rate between G and I regimens. If the patients with coronary abnormalities before IVIG were excluded, the prevention rates of coronary abnormalities were 50.0%, 49.2%, 100%, 100%, respectively, in the different regimens of IVIG in this study. For the prevention of coronary dilation/aneurysm, at acute stage, I regimen was better than G regimen in 400 mg/kg/day 5daysor 2gm/kg 1 dose, but there were no statistical differences among convalescent stage, long-term follow-up and retreatment with IVIG rate between G regimen and I regimen, even in 400 mg/kg/day 5daysor2gm/kg 1 dose. ACKNOWLEDGMENT We are grateful for support from the Cardiac Children s Foundation, R.O.C. REFERENCES 1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16: Taubert KA, Rowley AH, Shulman ST. Seven-year national survey of Kawasaki disease and acute rheumatic fever. Pediatr Infect Dis J 1994;13: Fischer P, Uttenreuther-Fischer MM, Naoe S, et al. Kawasaki disease: update on diagnosis, treatment, and a still controversial etiology. Pediatr Hematol Oncol 1996;13: Sundel RP. Update on the treatment of Kawasaki disease in childhood. Curr Rheumatol Rep 2002;4: Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: Barron KS. Kawasaki disease. Epidemiology, late prognosis, and therapy. Rheum Dis Clin North Am 1991;17: Yanagawa H, Yashiro M, Nakamura Y, et al. IV gamma globulin treatment of Kawasaki disease in Japan: results of a nationwide survey. Acta Paediatr 1995;84: Barron KS, Murphy DJ Jr, Silverman ED, et al. Treatment of Kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. J Pediatr 1990; 117: Hwang B, Lin CY, Hsieh KS, et al. High-dose intravenous gamma globulin therapy in Kawasaki disease. Acta Peadiatr Sinica 1989;30: Engle MA, Fatica NS, Bussel JB, et al. Clinical trial of single-dose intravenous gamma globulin in acute Kawasaki disease: Preliminary report. Am J Dis Child 1989;143: Sundel RP. Update on the treatment of Kawasaki disease in childhood. Curr Rheumatol Rep 2002;4: Research Committee on Kawaski disease. Report of Subcommittee on standarization of diagnostic criteria and report of coronary artery lesions in Kawasaki disease. Tokyo: Ministry of Health and Welfare, Jiao F, Yang L, Li Y, et al. Epidemiologic and clinical characteristics of Kawasaki disease in Shaanxi Province, China, J Trop Pediatr 2001;47: Hwang KP, Wu IR, Huang LY, et al. Clinical manifestations and effects of IVGG in patients with Kawasaki disease. Kaohsiung J Med Sci 1996;12: Sato N, Sugimura T, Akagi T, et al. Selective high dose gammaglobulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatr Int 1999;41: Tsai MH, Yen MH, Huang YC, et al. Intravenous immunoglobulin treatment in Kawasaki disease: effective in all brands. The 171 st Scientific Meeting of Taiwan Pediatric Association, oral presention. 19 Acta Cardiol Sin 2004;20:15 20
Coronary Artery Complications in Pediatric Patients with Kawasaki Disease: A 12-Year National Survey
Original Article Acta Cardiol Sin 2013;29:357 365 Pediatric Cardiology Coronary Artery Complications in Pediatric Patients with Kawasaki Disease: A 12-Year National Survey Chun-Yen Chiang, 1 Chung-Han
More informationThe Relationship between Coronary Artery Aneurysm and QT Interval Dispersion in Acute Phase of Kawasaki Disease
Original Article Iran J Pediatr Jun 2011; Vol 21 (No 2), Pp: 220-224 The Relationship between Coronary Artery Aneurysm and QT Interval Dispersion in Acute Phase of Kawasaki Disease Abdolrazagh Kiani 1,
More informationKawasaki disease (KD) is associated with
Intravenous immunoglobulin 1 g/kg as the initial treatment for Kawasaki disease Hirohiko Shiraishi, Mayu Iino, Masaru Hoshina, Kou Ichihashi, Mariko Y Momoi Tochigi, Japan Background: Coronary artery lesion
More informationKawasaki Disease: A Retrospective Study
Bahrain Medical Bulletin, Vol. 28, No. 2, June 2006 Kawasaki Disease: A Retrospective Study Z. Al-Mosawi, MBBCH, ABMS-Ped* A.M. Mohammad, MD, FAAP * A.N. Al-Saif, MD, FRCPI, DCH* A.R. Al Madhoob, MBBCH,
More informationKey Words: C-reactive protein, cholesterol HDL, coronary artery disease, Kawasaki disease
ORIGINAL ARTICLE Significant Relationship Between Serum High-sensitivity C-Reactive Protein, High-density Lipoprotein Cholesterol Levels and Children With Kawasaki Disease and Coronary Artery Lesions Chun-Yen
More informationNovel Biomarker for Diagnosis of Kawasaki Diseases
11 th International Kawasaki Disease Symposium Novel Biomarker for Diagnosis of Kawasaki Diseases 2015 Feb 4 th Tai-Ming Ko Jer-Yuarn Wu, Yuan-Tsong Chen DISCLOSURES: None Biomarkers for human disease
More informationKawasaki Disease in the Older Child
Kawasaki Disease in the Older Child Tarek Momenah, MBBS, DCH, FAAP, FRCP; Shubhayan Sanatani, BSc, MD, FRCP; Jim Potts, PhD; George G. S. Sandor, MB, ChB, DCH, FRCP, FACC; Derek G. Human, MA, BM, BCh,
More informationReaction at the Bacillus CalmetteeGuérin Inoculation Site in Patients with Kawasaki Disease
Pediatrics and Neonatology (2013) 54, 43e48 Available online at www.sciencedirect.com journal homepage: http://www.pediatr-neonatol.com ORIGINAL ARTICLE Reaction at the Bacillus CalmetteeGuérin Inoculation
More informationClinical Guidance. Kawasaki disease. Summary This guideline includes therapy and follow up including investigations (echocardiography, MRI).
Clinical Guidance Kawasaki disease Summary This guideline includes therapy and follow up including investigations (echocardiography, MRI). Document Detail Document type Clinical Guideline Document name
More informationThe Harada Score in the US Population of Children With Kawasaki Disease
RESEARCH ARTICLE The Harada Score in the US Population of Children With Kawasaki Disease AUTHORS Helen Tewelde, MD, 1 Jeein Yoon, MD, 2 Wendy Van Ittersum, MD, 2 Sarah Worley, MS, 3 Tamar Preminger, MD,
More informationClinical Manifestations of Kawasaki Disease: What Are the Significant Parameters?
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2009) 27: 131-136 Clinical Manifestations of Kawasaki Disease: What Are the Significant Parameters? Kanoknaphat Chaiyarak 1, Kritvikrom Durongpisitkul 2,
More informationResearch Article Sonographic Gallbladder Abnormality Is Associated with Intravenous Immunoglobulin Resistance in Kawasaki Disease
The Scientific World Journal Volume 2012, Article ID 485758, 5 pages doi:10.1100/2012/485758 The cientificworldjournal Research Article Sonographic Gallbladder Abnormality Is Associated with Intravenous
More informationCase Presentation. By Eman El Sharkawy Ass. Professor of cardiology Alexandria University
Case Presentation By Eman El Sharkawy Ass. Professor of cardiology Alexandria University 6m old baby girl Past history : - At the age of 2m attack of fever, diarrhea, mouth ulcers, difficult breast feeding
More informationPyuria is not always sterile in children with Kawasaki disease
113..117 Pediatrics International (2010) 52, 113 117 doi: 10.1111/j.1442-200X.2009.02884.x Original Articleped_2884 Pyuria is not always sterile in children with Kawasaki disease Sheng-Ling Jan, 1,2 Meng-Che
More informationNon-Responders to Intravenous Immunoglobulin and Coronary Artery Dilatation in Kawasaki Disease: Predictive Parameters in Korean Children
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Non-Responders to Intravenous Immunoglobulin and Coronary Artery Dilatation in Kawasaki Disease: Predictive Parameters
More informationIntravenous immunoglobulin therapy for infants with Kawasaki diseaseyounger than 6 months
IOSR Journal Of Pharmacywww.iosrphr.org (e)-issn: 220-303, (p)-issn: 239-29 Volume 6, Issue 2 Version. (Dec 206), PP. -6 Intravenous immunoglobulin therapy for infants with Kawasaki diseaseyounger than
More informationRisk factors for persistence of coronary artery abnormalities in Turkish children with Kawasaki disease
The Turkish Journal of Pediatrics 2015; 57: 248-253 Original Risk factors for persistence of coronary artery abnormalities in Turkish children with Kawasaki disease Murat Muhtar Yılmazer 1, Taliha Öner
More informationKawasaki disease. Dr Laurence Lacroix
Dr Laurence Lacroix 16.04.2014 1 2 DEFINITION: o Kawasaki disease(kd) is an acute febrile illness of childhood ovasculitisof medium-sized extraparenchymal arteries o Predilection for coronary arteries
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationARTICLE. Prevalence of Coronary Artery Lesions on the Initial Echocardiogram in Kawasaki Syndrome
ARTICLE Prevalence of Coronary Artery Lesions on the Initial Echocardiogram in Kawasaki Syndrome Aryeh Z. Baer, MD; Lorry G. Rubin, MD; Craig A. Shapiro, BA; Sunil K. Sood, MD; Sujatha Rajan, MD; Yehuda
More informationIL-6) (Kawasaki disease) -α(tumor necrosis factor-α, TNF-α) -6(interleukin-6, ; 27: DOI: / [4] [5] [1,2] [6]
[] 57 1 林 2 1 540 107 5 5-7 10 2017; 27: 57-64 DOI: 10.3966/168232812017032701008 (Kawasaki disease) [1,2] 1967 [1] 1976 [3] -α(tumor necrosis factor-α, TNF-α)-6(interleukin-6, IL-6) [4] 10 5 19 [5] 1996
More informationCoronary artery status of patients with transient fever h after first IVIG infusion did not differ from that seen in responsive patients
Baek et al. Pediatric Rheumatology (2018) 16:83 https://doi.org/10.1186/s12969-018-0301-6 RESEARCH ARTICLE Coronary artery status of patients with transient fever 24 36 h after first IVIG infusion did
More informationVasculitis local: systemic
Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated 2- infectious
More informationUsefulness intravenous immunoglobulin therapy
Usefulness of initial single intravenous immunoglobulin therapy for Kawasaki disease Toshimasa Nakada Department of Pediatrics, Aomori Prefectural Central Hospital Kawasaki disease Kawasaki disease is
More informationRecurrent Kawasaki disease: USA and Japan
Recurrent Kawasaki disease: USA and Japan Ryan A. Maddox, Centers for Disease Control and Prevention Robert C. Holman, Centers for Disease Control and Prevention Ritei Uehara, Utsunomiya City Public Health
More informationKawasaki Disease: What you need to know from the 2017 Guidelines
Kawasaki Disease: What you need to know from the 2017 Guidelines S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 No disclosures to report Outline
More informationTreatment of Kawasaki disease by different doses of immunoglobulin: a meta analysis of efficacy and safety
Review Article Treatment of Kawasaki disease by different doses of immunoglobulin: a meta analysis of efficacy and safety Jing Chen, Bin Ma, Li-Xing Lin, Yi-Ming Xue Department of Pediatrics, First Clinical
More informationHigh Sensitivity C Reactive Protein (hs-crp) in Adolescent and Young Adult Patients with History of Kawasaki Disease
Mini Forum for Pediatric Cardiac Disease in Young Adulthood Acta Cardiol Sin 2015;31:473 477 doi: 10.6515/ACS20150424E High Sensitivity C Reactive Protein (hs-crp) in Adolescent and Young Adult Patients
More informationKawasaki Disease. 1:45 2:30 p.m. James Nocton, MD Benjamin Goot, MD. Children s Specialty Group. All rights reserved.
Kawasaki Disease 1:45 2:30 p.m. James Nocton, MD Benjamin Goot, MD Disclosures We have no relevant financial relationships to disclose. Objectives Describe the characteristic signs and symptoms of Kawasaki
More informationKawasaki disease (KD) is an acute inflammatory
ORIGINAL ARTICLE Evaluation of Kawasaki Disease Risk Scoring System in a Single Center Experience from Japan Miho Ashiarai, Asami Shinbo, Kazuaki Matsumoto, Hisae Nakatani, Keiko Onda, Mari Okada, Masako
More informationVarious coronary artery complications of Kawasaki disease: Series of 5 cases and review of literature
JCDR Clinical Case Report Based Study Various coronary artery complications of Kawasaki disease: Series of 5 cases and review of literature Saroj Mandal 1, Arindam Pande 1, Debosmita Mandal 2, Achyut Sarkar
More informationCatheter Interventions for Kawasaki Disease: Current Concepts and Future Directions
REVIEW DOI 10.4070/kcj.2011.41.2.53 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright 2011 The Korean Society of Cardiology Open Access Catheter Interventions for Kawasaki Disease: Current Concepts
More informationDOI: /peds The online version of this article, along with updated information and services, is located on the World Wide Web at:
Performance of 2004 American Heart Association Recommendations for Treatment of Kawasaki Disease Elizabeth S. Yellen, Kimberlee Gauvreau, Masato Takahashi, Jane C. Burns, Stanford Shulman, Annette L. Baker,
More informationHo-Chang Kuo 1,2, Mindy Ming-Huey Guo 1,2, Mao-Hung Lo 1,2, Kai-Sheng Hsieh 1,2 and Ying-Hsien Huang 1,2,3*
Kuo et al. BMC Pediatrics (2018) 18:200 https://doi.org/10.1186/s12887-018-1180-1 STUDY PROTOCOL Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose
More informationEffects of Arsenic Trioxide on Electrocardiography
Original Article Acta Cardiol Sin 2004;20:1 6 Electrophysiology Effects of Arsenic Trioxide on Electrocardiography Tu-Ying Liu, 1 Hsiang-Ning Luk, 2 Tsui-Min Wang, 3 Philip Yu-An Ding 1 and Chern-En Chiang
More informationTHE EFFECTIVENESS OF IVIG ON TREATING KAWASAKI DISEASE AND, PREVENTING CARDIAC ANEURYSM: A REVIEW ARTICLE
wjpmr, 2017,3(3), 07-11 SJIF Impact Factor: 4.103 Review Article WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH ISSN 2455-3301 www.wjpmr.com WJPMR THE EFFECTIVENESS OF IVIG ON TREATING KAWASAKI DISEASE
More informationVasculitis local: systemic
Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated inflammation
More informationRESUME Sep National Medical License, Taiwan Oct Board of Interal Medicine, Taiwan Aug Board of Cardiology, Internal Medicine, Taiwan
RESUME Ye-Hsu Lu, M.D. Office Address: No.100, Ziyou 1st Rd., Sanmin Dist., Kaohsiung City 80708, Taiwan TEL: +886-7-3121101 ext. 7741 (Office), +886-918867017 (Cell) FAX: +886-7-3234845 E-mail: yehslu@gmail.com
More informationHISTORICAL ASPECTS CLINICAL FEATURES...405
CLINICAL MICROBIOLOGY REVIEWS, July 1998, p. 405 414 Vol. 11, No. 3 0893-8512/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Kawasaki Syndrome ANNE H. ROWLEY 1 * AND
More informationEpidemiologic Features of Kawasaki Disease in Taiwan,
ARTICLE Epidemiologic Features of Kawasaki Disease in Taiwan, 23 26 Wen-Chan Huang, MD a, Li-Min Huang, MD, PhD a, I-Shou Chang, PhD b, Luan-Yin Chang, MD, PhD a, Bor-Luen Chiang, MD, PhD a,c, Pei-Jer
More informationKawasaki Disease Reconsidered New AHA Guidelines
Kawasaki Disease Reconsidered New AHA Guidelines John Darby, MD Nisha Tamaskar, MD Stanford Shulman, MD Marietta DeGuzman, MD Kristin Sexson, MD, PhD Introductions John Darby, MD Texas Children s Hospital,
More informationKawasaki disease (KD) is an acute febrile vasculitis that is usually observed in
Original Article Iraj Mohammadzadeh (MD) 1 Somayyeh Noei (MD) 1 Kazem Babazadeh (MD) 1 Hassan Zamani (MD) 1 Rahim Barari-Savadkoohi (MD) 2 Reza Alizadeh-Navaei (MD) 3* 1. Non-Communicable Pediatric Research
More informationLong-Term Prognosis for Patients with Kawasaki Disease Complicated by Large Coronary Aneurysm (diameter 6 mm)
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Long-Term Prognosis for Patients with Kawasaki Disease Complicated by Large Coronary Aneurysm (diameter 6 mm) Ji
More informationMedium-dose IVIG (1 g/kg) as an initial treatment of Kawasaki disease
Original article Moon Korean KP, J Pediatr et al. 2016;59(4):178-182 Medium-dose IVIG (1 g/kg) as an initial treatment of Kawasaki disease pissn 1738-1061 eissn 2092-7258 Korean J Pediatr Prediction of
More informationDespite the availability of an effective treatment of Kawasaki
ORIGINAL STUDIES Delayed Diagnosis by Physicians Contributes to the Development of Coronary Artery Aneurysms in Children With Matthew S. Wilder, MD,* Lawrence A. Palinkas, PhD,* Annie S. Kao, MPH, PhD,
More informationClinical Characteristics of Kawasaki Disease in Infants Younger than Six Months: A Single-Center Study
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Clinical Characteristics of Kawasaki Disease in Infants Younger than Six Months: A Single-Center Study You Min Yoon,
More informationAssociation of Sterile Pyuria and Coronary Artery Aneurysm in Kawasaki Syndrome
ORIGINAL REPORT Association of Sterile Pyuria and Coronary Artery Aneurysm in Kawasaki Syndrome Mohsen Akhavan Sepahi 1, Reza Miri 2, and Hasan Taher Ahmadi 3 1 Department of Pediatric Nephrology, Qom
More informationKawasaki disease: echocardiographic features in 91
1142 Archives ofdisease in Childhood 1990; 65: 1142-1146 Hospital for Sick Children, Great Ormond Street, London WC1N 3JH Department of Paediatric Cardiology A Suzuki V Gooch S G Haworth Department of
More informationpissn: , eissn: Yonsei Med J 55(5): , 2014
Original Article http://dx.doi.org/10.3349/ymj.2014.55.5.1260 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 55(5):1260-1266, 2014 Clinical Outcomes of Initial Dexamethasone Treatment Combined with a
More informationAreca Nut Chewing Complicated with Non-Obstructive and Obstructive ST Elevation Myocardial Infarction
Case Report Acta Cardiol Sin 2016;32:103 107 doi: 10.6515/ACS20141225A Areca Nut Chewing Complicated with Non-Obstructive and Obstructive ST Elevation Myocardial Infarction Ying-Chih Chen, 1 Hsiang-Chun
More informationKawasaki Disease: An Update
Kawasaki Disease: An Update Mary Beth Son, MD Boston Children s Hospital September 23 rd, 2018 No disclosures relevant to this talk Outline of Talk Signs and Symptoms of KD Diagnosis Treatment knowns and
More informationST - segment Elevation Myocardial Infarction complicating an atypical Kawasaki disease
ST - segment Elevation Myocardial Infarction complicating an atypical Kawasaki disease Raluca PRISECARU, Marc VINCENT, Steven VERCAUTEREN Brussels Heart Center, Brussels, Belgium Disclosure None Clinical
More informationCLINICAL REVIEW. Kawasaki disease. Anthony Harnden, 1 Masato Takahashi, 2 David Burgner 3. For the full versions of these articles see bmj.
For the full versions of these articles see bmj.com CLINICAL REVIEW Kawasaki disease Anthony Harnden, 1 Masato Takahashi, 2 David Burgner 3 1 Department of Primary Health Care, University of Oxford, Headington,
More informationSetting The setting was tertiary care. The economic study was conducted in Bangkok, Thailand.
A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease Arj-Ong S, Lertsapcharoen P, Thisyakorn C, Chotivitayatarakorn P, Khongphatthanayothin A Record Status
More informationCase Report Incomplete Kawasaki disease: The usefulness of BCG reactivation as a diagnostic tool
Case Report Incomplete Kawasaki disease: The usefulness of BCG reactivation as a diagnostic tool Omer S.M. Suliman, Mohamed Abdelnasser Department of Paediatrics, AlRass General Hospital, Saudi Arabia
More informationSUCCESSFUL HOME INR MONITORING FOLLOWING KAWASAKI DISEASE
The West London Medical Journal 2013 Vol 5 No 2 pp 11-15 SUCCESSFUL HOME INR MONITORING FOLLOWING KAWASAKI DISEASE Bushra Ahmed ABSTRACT Camilla Sen Colin Michie Most paediatricians will encounter at least
More informationTwo Cases of Super-Giant Coronary Aneurysms after Kawasaki Disease
Case Report Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Two Cases of Super-Giant Coronary neurysms after Kawasaki Disease Joowon Lee, MD, Gi eom Kim, MD, o Sang Kwon, MD, Eun
More informationKawasaki Disease. Chapter Tomisaku Kawasaki
Chapter 26.11 Kawasaki Disease Tomisaku Kawasaki Kawasaki disease (KD) is an acute febrile mucocutaneous lymph node syndrome with multisystem vasculitis mainly affecting infants and small children less
More informationCoronary Diameters in Taiwanese Children Younger than 6 Years Old: Z-Score Regression Equations Derived from Body Surface Area
Original Article Acta Cardiol Sin 2014;30:266 273 Pediatric Cardiology Coronary Diameters in Taiwanese Children Younger than 6 Years Old: Z-Score Regression Equations Derived from Body Surface Area Ming-Tai
More informationConcurrent Subarachnoid Hemorrhage and Acute Myocardial Infarction: A Case Report
Concurrent subarachnoid hemorrhage and AMI 155 Concurrent Subarachnoid Hemorrhage and Acute Myocardial Infarction: A Case Report Chen-Chuan Cheng 1, Wen-Shiann Wu 1, Chun-Yen Chiang 1, Tsuei-Yuang Huang
More informationN-Terminal Pro-Brain Natriuretic Peptide as a Useful Diagnostic Marker of Acute Kawasaki Disease in Children
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Advance Publication by-j-stage N-Terminal Pro-Brain Natriuretic Peptide as a Useful Diagnostic Marker of
More informationDiagnosis of Incomplete Kawasaki Disease in Infants Based on an Inflammation at the Bacille Calmette-Guérin Inoculation Site
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Diagnosis of Incomplete Kawasaki Disease in Infants Based on an Inflammation at the Bacille Calmette-Guérin Inoculation
More informationCASE REPORT: A THREE-MONTH-OLD BOY WITH INCOMPLETE KAWASAKI DISEASE AND EARLY SUPER-GIANT CORONARY ANEURYSM RESULTING IN DETRIMENTAL CARDIAC FUNCTION
CASE REPORT: A THREE-MONTH-OLD BOY WITH INCOMPLETE KAWASAKI DISEASE AND EARLY SUPER-GIANT CORONARY ANEURYSM RESULTING IN DETRIMENTAL CARDIAC FUNCTION Prakul Chanthong, Pornrawee Plearntummakun, Chodchanok
More informationKawasaki syndrome (KS) is an acute, vasculitic
Delayed Diagnosis of Kawasaki Syndrome: An Analysis of the Problem Marsha S. Anderson, MD; James K. Todd, MD; and Mary P. Glodé, MD ABSTRACT. Objective. Most pediatric providers in Colorado are familiar
More informationFacilitated Percutaneous Coronary Intervention in STEMI Patients: Does It Work in Asian Patients?
Editorial Comment Acta Cardiol Sin 2014;30:292 297 Facilitated Percutaneous Coronary Intervention in STEMI Patients: Does It Work in Asian Patients? Wei-Chun Huang, 1,2,3 Cheng-Hung Chiang 1,2 and Chun-Peng
More informationP E R S P E C T I V E. Kawasaki Disease An Indian Perspective
P E R S P E C T I V E Kawasaki Disease An Indian Perspective SURJIT SINGH AND *TOMISAKU KAWASAKI From the Pediatric Allergy and Immunology Unit, Advanced Pediatric Center, PGIMER, Chandigarh, India; and
More informationRole of Anti-neutrophil Cytoplasmic Antibodies in Kawasaki Disease
J Med Sci 2012;32(3):129-134 http://jms.ndmctsgh.edu.tw/3203129.pdf Copyright 2012 JMS Fang-Yih Liaw, et al. Role of Anti-neutrophil Cytoplasmic Antibodies in Kawasaki Disease Fang-Yih Liaw 1, Ming-Chih
More informationNoncoronary Cardiac Abnormalities Are Associated With Coronary Artery Dilation and With Laboratory Inflammatory Markers in Acute Kawasaki Disease
Journal of the American College of Cardiology Vol. 57, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.08.619
More informationRisk Factors of Resistance to Intravenous Immunoglobulin in patients with Kawasaki: A Cross-Sectional Study Over a 10 Year Period ( )
Risk Factors of Resistance to Intravenous Immunoglobulin in patients with Kawasaki: A Cross-Sectional Study Over a 10 Year Period (2006-2016) Fariba Tarhani (1) Azadeh Jafrasteh (2) Mahshid Garmsiri (3)
More informationHow bout Them Steroids: The Role of Corticosteroids in Kawasaki Disease
How bout Them Steroids: The Role of Corticosteroids in Kawasaki Disease Source: http://blog.timesunion.com/mdtobe/answer-to-medical-mystery-monday-65/1885/ Pharmacotherapy Grand Rounds Meenakshi R. Ramanathan,
More informationThe role of echocardiography in Kawasaki disease
International Journal of Rheumatic Diseases 2018; 21: 50 55 SPECIAL ISSUE KAWASAKI DISEASE The role of echocardiography in Kawasaki disease Brian W. MCCRINDLE and Barbara CIFRA Labatt Family Heart Centre,
More informationACUTE CARBON MONOXIDE POISONING RESULTING
ACUTE CARBON MONOXIDE POISONING RESULTING IN ST ELEVATION MYOCARDIAL INFARCTION: A RARE CASE REPORT Po-Chao Hsu, 1 Tsung-Hsien Lin, 1,2 Ho-Ming Su, 1,2 Hsiang-Chun Lee, 1 Chih-Hsin Huang, 1 Wen-Ter Lai,
More informationPackage leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration
: Information for the user HEPATECT CP 50 IU/ml solution for infusion Human hepatitis B immunoglobulin for intravenous administration Read all of this leaflet carefully before you start using this medicine
More informationISPUB.COM. Kawasaki Disease: An Incomplete Presentation. G Gangadhara Rao, S Sadagopan, J Gnanapragasam CASE REPORT
ISPUB.COM The Internet Journal of Pediatrics and Neonatology Volume 7 Number 1 G Gangadhara Rao, S Sadagopan, J Gnanapragasam Citation G Gangadhara Rao, S Sadagopan, J Gnanapragasam.. The Internet Journal
More informationCase report. Open Access. Abstract
Open Access Case report Incomplete, atypical kawasaki disease or evolving systemic juvenile idiopathic arthritis: a case report Shakeel Shaikh 1, Sidra Ishaque 2 * and Taimur Saleem 2 Addresses: 1 Department
More informationEarly features of Kawasaki disease with pyuria in febrile infants younger than 6 months
Yoon et al. BMC Pediatrics (2018) 18:389 https://doi.org/10.1186/s12887-018-1362-x RESEARCH ARTICLE Open Access Early features of Kawasaki disease with pyuria in febrile infants younger than 6 months Seo
More informationSupplementary Online Content
Supplementary Online Content Chen S, Dong Y, Wang J, et al. Coronary artery complication in Kawasaki disease and the importance of early intervention (the International CAKE Study): a systematic review
More informationKawasaki Disease: Pathophysiology, Clinical Manifestations, and Management
Curr Rheumatol Rep (2014) 16:423 DOI 10.1007/s11926-014-0423-x VASCULITIS (LR ESPINOZA, SECTION EDITOR) Kawasaki Disease: Pathophysiology, Clinical Manifestations, and Management Victoria R. Dimitriades
More informationKawasaki disease (KD) is an acute systemic vasculitis of unknown etiology that primarily affects small- and mediumsized
N-Terminal Pro-Brain Natriuretic Peptide and Risk of Coronary Artery Lesions and Resistance to Intravenous Immunoglobulin in Kawasaki Disease Ken Yoshimura, MD, Takahisa Kimata, MD, Kenji Mine, MD, Takamichi
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationIron deficiency anemia as a predictor of coronary artery abnormalities in Kawasaki
Iron deficiency anemia as a predictor of coronary artery abnormalities in Kawasaki disease Running title: Kawasaki disease with iron deficiency anemia Sohyun KIM, M.D., Lucy Youngmin EUN, M.D., Ph.D. Departments
More informationLong-Term Prognosis in Recipients of Implantable Cardioverter-Defibrillators for Secondary Preventions in Taiwan A Multicenter Registry Study
Mini Forum for EPS Acta Cardiol Sin 2014;30:22 28 Long-Term Prognosis in Recipients of Implantable Cardioverter-Defibrillators for Secondary Preventions in Taiwan A Multicenter Registry Study Tze-Fan Chao,
More informationInterventional Treatment for Complete Occlusion of Arteriovenous Shunt: Our Experience in 39 cases
Chin J Radiol 2003; 28: 137-142 137 Interventional Treatment for Complete Occlusion of Arteriovenous Shunt: Our Experience in 39 cases SHE-MENG CHENG SUK-PING NG FEI-SHIH YANG SHIN-LIN SHIH Department
More informationCorticosteroids for the treatment of Kawasaki disease in children(review)
Cochrane Database of Systematic Reviews Corticosteroids for the treatment of Kawasaki disease in children(review) Wardle AJ, Connolly GM, Seager MJ, Tulloh RMR Wardle AJ, Connolly GM, Seager MJ, Tulloh
More informationKawasaki disease: two case reports from the Aga Khan Hospital, Dar es Salaam- Tanzania
Noorani and Lakhani BMC Pediatrics (2018) 18:334 https://doi.org/10.1186/s12887-018-1306-5 CASE REPORT Open Access Kawasaki disease: two case reports from the Aga Khan Hospital, Dar es Salaam- Tanzania
More informationContinuous Infusion of Cyclosporin A in Intravenous Immunoglobulin Resistant Kawasaki Disease Patients
Case Report Continuous Infusion of Cyclosporin A in Intravenous Immunoglobulin Resistant Kawasaki Disease Patients Takaomi Minami, Hirohiko Shiraishi, Kensuke Oka, Jun Odaka, Tomoyuki Ishii, Akiko Takata,
More informationKawasaki disease in infants
Review article Korean J Pediatr Kawasaki disease in infants Jung Sook Yeom, MD, Hyang Ok Woo, MD, Ji Sook Park, MD, Eun Sil Park, MD, Ji-Hyun Seo, MD, Hee-Shang Youn, MD Department of Pediatrics, Gyeongsang
More informationInfection & Chemotherapy. Original Article. Hye Rim Park 1, Mi Young Han 2, Kyung Lim Yoon 2, Sung-Ho Cha 1, Sung Kyoung Moon 3, and Hae Woon Jung 1
Original Article https://doi.org/10.3947/ic.2017.49.1.38 Infect Chemother 2017;49(1):38-43 ISSN 2093-2340 (Print) ISSN 2092-6448 (Online) Infection & Chemotherapy Mycoplasma Infection as a Cause of Persistent
More informationCorrelations of complication with coronary arterial lesion with VEGF, PLT, D-dimer and inflammatory factor in child patients with Kawasaki disease
European Review for Medical and Pharmacological Sciences 2018; 22: 5121-5126 Correlations of complication with coronary arterial lesion with VEGF, PLT, D-dimer and inflammatory factor in child patients
More informationAge-adjusted plasma N-terminal pro-brain natriuretic peptide level in Kawasaki disease
Original article Jun Korean H, et J Pediatr al. Age-adjusted 2016;59(7):298-302 plasma NT-proBNP level and Kawasaki disease pissn 1738-1061 eissn 2092-7258 Korean J Pediatr Age-adjusted plasma N-terminal
More informationKawasaki Disease: Updates on Diagnosis, Treatment, and Management
Kawasaki Disease: Updates on Diagnosis, Treatment, and Management Kristin C. Lombardi, M.D. Assistant Professor of Pediatrics, Clinical Educator The Warren Alpert Medical School of Brown University Pediatric
More informationKAWASAKI DISEASE IN GHANA: CASE REPORTS FROM KORLE BU TEACHING HOSPITAL
KAWASAKI DISEASE IN GHANA: CASE REPORTS FROM KORLE BU TEACHING HOSPITAL E. V. BADOE 1, J. NEEQUAYE 1, J. O. OLIVER-COMMEY 1, J. AMOAH 2, A. OSAFO 2, I. ARYEE 2 and M. Y. NYARKO 3 1 Department of Child
More informationKey words: Mucocutaneous Lymph Node Syndrome, Incidence Rate, Geographical Distribution, Temporal Distribution, Japan. METHODS
doi:10.2188/jea.je2008030 Original Article Monthly Observation of the Number of Patients with Kawasaki Disease and its Incidence Rates in Japan: Chronological and Geographical Observation from Nationwide
More informationProfile of Kawasaki disease in children referred to two pediatric rheumatology services in Rio de Janeiro, Brazil
ORIGINAL ARTICLE Profile of Kawasaki disease in children referred to two pediatric rheumatology services in Rio de Janeiro, Brazil Rozana Gasparello de Almeida 1, Andréa Valentim Goldenzon 2, Marta Cristine
More informationKawasaki disease: multiple giant coronary aneurysms intervention and pacemaker implantation due to complete heart block a case report
Case Report Kawasaki disease: multiple giant coronary aneurysms intervention and pacemaker implantation due to complete heart block a case report Chunping Liu, Junxia Li, Zhenshuang Cui, Lili Niu, Junyu
More informationCoronary Heart Disease
Coronary Heart Disease Elevated Levels of High-Sensitivity C-Reactive Protein and Serum Amyloid-A Late After Kawasaki Disease Association Between Inflammation and Late Coronary Sequelae in Kawasaki Disease
More informationAn Open Randomized Study Prague-5 ˆ
Next Day Discharge After Successful Primary Angioplasty for Acute ST Elevation Myocardial Infarction An Open Randomized Study Prague-5 Radovan JIRMÁR, 1 MD, Petr WIDIMSKÝ, 1 MD, Jan CAPEK, 1 MD, Ota HLINOMAZ,
More informationCurrent recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications
European Review for Medical and Pharmacological Sciences 2007; 11: 301-308 Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications
More informationPrediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring
Prediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring Yu-Zhen ZHANG, M.D.,* Shi-Wen WANG, M.D.,* Da-Yi Hu, M.D.,**
More information